News
XGN
8.25
-2.02%
-0.17
Weekly Report: what happened at XGN last week (1005-1009)?
Weekly Report · 17h ago
Weekly Report: what happened at XGN last week (0928-1002)?
Weekly Report · 10/05 09:15
Weekly Report: what happened at XGN last week (0921-0925)?
Weekly Report · 09/28 09:14
Craig-Hallum sees potential for confusion after CMS fee schedule
TipRanks · 09/22 13:55
Exagen (XGN) Receives a Buy from Roth MKM
TipRanks · 09/22 13:15
Weekly Report: what happened at XGN last week (0914-0918)?
Weekly Report · 09/21 09:14
Weekly Report: what happened at XGN last week (0907-0911)?
Weekly Report · 09/14 09:14
Weekly Report: what happened at XGN last week (0831-0904)?
Weekly Report · 09/07 09:13
Exagen Insider Move: CFO Unloads a Significant Block of Shares
TipRanks · 09/03 02:08
Exagen participates in a conference call with Craig-Hallum
TipRanks · 08/31 16:25
Weekly Report: what happened at XGN last week (0824-0828)?
Weekly Report · 08/31 09:15
Weekly Report: what happened at XGN last week (0817-0821)?
Weekly Report · 08/24 09:15
Weekly Report: what happened at XGN last week (0810-0814)?
Weekly Report · 08/17 09:15
Weekly Report: what happened at XGN last week (0803-0807)?
Weekly Report · 08/10 09:14
Exagen Is Maintained at Buy by TD Cowen
Dow Jones · 08/05 19:46
Exagen Price Target Raised to $10.00/Share From $8.00 by TD Cowen
Dow Jones · 08/05 19:46
TD Cowen Maintains Buy on Exagen, Raises Price Target to $10
Benzinga · 08/05 19:36
Exagen price target raised to $9 from $8 at BTIG
TipRanks · 08/05 14:24
Exagen price target raised to $12 from $8 at B. Riley
TipRanks · 08/05 14:08
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Exagen (XGN) and Warby Parker (WRBY)
TipRanks · 08/05 13:20
More
Webull provides a variety of real-time XGN stock news. You can receive the latest news about Exagen Inc. through multiple platforms. This information may help you make smarter investment decisions.
About XGN
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.